---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000057"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:46:05.151354+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas and Pfizer report Phase 3 VERITAC-2 hit: vepdegestrant improves PFS in ESR1m breast cancer; ITT miss

## Summary
- Vepdegestrant met primary endpoint in ESR1m population: statistically significant PFS improvement, exceeded target HR of 0.60.
- ITT population did not achieve statistical significance for PFS.
- Overall survival not mature (<25% of required events); trial continuing.
- Safety profile consistent with prior studies; detailed results to be submitted to medical meeting and regulators.
- First PROTAC degrader to show Phase 3 clinical benefit; Fast Track designation previously granted.

## SEC filing metadata
- accession: 0001655759-25-000057
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/0001655759-25-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/arvn-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000057
- JSON: https://secwatch.observer/filing/0001655759-25-000057.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.